From checking in amid the L.A. fires to supporting each other's careers, Quaid says the star-studded cast still chats ...

Christopher Nolan doesn't need an image to maintain; from Following (1998) to Oppenheimer (2023), fans know what's in store ...

In a report released on March 14, Matthew Biegler from Oppenheimer reiterated a Buy rating on Allogene Therapeutics (ALLO – Research Report), ...

Who wins between Oppenheimer and The Odyssey for the most star-studded cast amongst Christopher Nolan's films?

Shares of Nektar Therapeutics (NASDAQ:NKTR) added ~9% in the premarket on Friday after Oppenheimer upgraded the biopharma to ...

Such an advance, leaders agree, would fundamentally transform society. Google CEO Sundar Pichai has repeatedly described AI ...

Expedia Group (NASDAQ:EXPE – Free Report) had its price objective trimmed by Oppenheimer from $235.00 to $230.00 in a ...

Oppenheimer analyst Michael Wiederhorn is updating its Amedisys (AMED) model following the Q4 earnings release. Amedisys is currently in the ...

(JTA) — Friday is not just “Barbie” release day — moviegoers are also planning to fill theaters across the United States to see Christopher Nolan’s “Oppenheimer” biopic. Many hope it ...

Netflix’s CCO Bela Bajaria believes Oppenheimer would have thrived on streaming. But would it really match its box office ...

AI, as an immortal intelligence, does not experience death, fear, or existential urgency. This raises profound questions: How ...

Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) was upgraded by equities research analysts at Oppenheimer from a “market ...